Small molecule · Inhibitor of D-alanyl-D-alanine cell wall precursors · developed by Baxter Hlthcare
Vancomycin is a branched tricyclic glycopeptide antibiotic that binds the D-alanyl-D-alanine ends of bacterial cell wall precursors, interfering with cell wall synthesis. It is used against Gram-positive bacterial infections, including MRSA and Clostridioides difficile infection, and is studied in cystic fibrosis, bacteremia and ulcerative colitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03595553 | Phase 3 | Clostridioides Difficile Infection | Completed | SMMT |
| NCT03181932 | Phase 3 | MRSA | Completed | SVRA |
| NCT02208063 | Phase 3 | Bacteremia | Terminated | CPIX |
| NCT04247542 | Phase 2 | Clostridium Difficile Infection | Completed | ACXP |
| NCT03759041 | Phase 2 | Ulcerative Colitis | Terminated | MCRB |
| NCT01746095 | Phase 2 | Cystic Fibrosis | Completed | SVRA |
| NCT00062647 | Phase 2 | Gram-Positive Bacterial Infections | Completed | CPIX |
| NCT03817125 | Phase 1 | Metastatic Melanoma | Completed | MCRB |
| NCT02618187 | Phase 1 | Ulcerative Colitis | Completed | MCRB |
| NCT01537666 | Phase 1 | Healthy | Completed | SVRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
BacteremiaClostridioides Difficile InfectionClostridium Difficile InfectionCystic FibrosisGram-Positive Bacterial InfectionsHealthyMetastatic MelanomaMRSAUlcerative Colitis
Updated Oct 11, 2026.